BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas. 2001;23:251-258. [PMID: 11590320 DOI: 10.1097/00006676-200110000-00005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Mita M, Tolcher AW. Novel apoptosis inducing agents in cancer therapy. Curr Probl Cancer 2005;29:8-32. [PMID: 15672328 DOI: 10.1016/j.currproblcancer.2004.11.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
2 Matsuda T, Almasan A, Tomita M, Tamaki K, Saito M, Tadano M, Yagita H, Ohta T, Mori N. Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand. J Gen Virol. 2005;86:1055-1065. [PMID: 15784899 DOI: 10.1099/vir.0.80531-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
3 Sanlioglu AD, Griffith TS, Omer A, Dirice E, Sari R, Altunbas HA, Balci MK, Sanlioglu S. Molecular mechanisms of death ligand-mediated immune modulation: a gene therapy model to prolong islet survival in type 1 diabetes. J Cell Biochem. 2008;104:710-720. [PMID: 18247339 DOI: 10.1002/jcb.21677] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
4 Chen C, Aldarouish M, Li Q, Liu X, Han F, Liu H, Qian Q. Triggered Immune Response Induced by Antigenic Epitopes Covalently Linked with Immunoadjuvant-Pulsed Dendritic Cells as a Promising Cancer Vaccine. J Immunol Res 2020;2020:3965061. [PMID: 32322595 DOI: 10.1155/2020/3965061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Fulda S. Targeting apoptosis signaling in pancreatic cancer. Cancers (Basel). 2011;3:241-251. [PMID: 24212616 DOI: 10.3390/cancers3010241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
6 Yuan K, Yong S, Xu F, Zhou T, McDonald JM, Chen Y. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer. Oncotarget 2015;6:25308-19. [PMID: 26320171 DOI: 10.18632/oncotarget.4490] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
7 Kang S, Park SY, Lee HJ, Yoo YH. TRAIL upregulates decoy receptor 1 and mediates resistance to apoptosis in insulin-secreting INS-1 cells. Biochem Biophys Res Commun 2010;396:731-5. [PMID: 20451496 DOI: 10.1016/j.bbrc.2010.05.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kaneko K, Satoh K, Masamune A, Satoh A, Shimosegawa T. Expression of ROCK-1 in human pancreatic cancer: its down-regulation by morpholino oligo antisense can reduce the migration of pancreatic cancer cells in vitro. Pancreas 2002;24:251-7. [PMID: 11893932 DOI: 10.1097/00006676-200204000-00007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 1.4] [Reference Citation Analysis]
9 Guo XR, Yang ZS, Tang XJ, Zou DD, Gui H, Wang XL, Ma SN, Yuan YH, Fang J, Wang B, Zhang L, Sun XY, Warnock GL, Dai LJ, Tu HJ. The application of mRNA-based gene transfer in mesenchymal stem cell-mediated cytotoxicity of glioma cells. Oncotarget 2016;7:55529-42. [PMID: 27487125 DOI: 10.18632/oncotarget.10835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Byeon HJ, Choi SH, Choi JS, Kim TH, Lee ES, Lee KC, Youn YS. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model. Biomed Pharmacother 2014;68:65-9. [PMID: 24268811 DOI: 10.1016/j.biopha.2013.10.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
11 DeRosier LC, Buchsbaum DJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, Wang W, Zhou T, Zinn KR, Long JW, Vickers SM. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 2007;13:5535s-43s. [PMID: 17875786 DOI: 10.1158/1078-0432.CCR-07-1075] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
12 Vogler M, Dürr K, Jovanovic M, Debatin K, Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 2007;26:248-57. [DOI: 10.1038/sj.onc.1209776] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 5.2] [Reference Citation Analysis]
13 Samm N, Werner K, Rückert F, Saeger HD, Grützmann R, Pilarsky C. The role of apoptosis in the pathology of pancreatic cancer. Cancers (Basel) 2010;3:1-16. [PMID: 24212603 DOI: 10.3390/cancers3010001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
14 Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med 2009;13:1221-7. [PMID: 19382915 DOI: 10.1111/j.1582-4934.2009.00748.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
15 Katz MH, Spivack DE, Takimoto S, Fang B, Burton DW, Moossa AR, Hoffman RM, Bouvet M. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann Surg Oncol. 2003;10:762-772. [PMID: 12900367 DOI: 10.1245/aso.2003.01.021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
16 Thomas RP, Farrow BJ, Kim S, May MJ, Hellmich MR, Evers BM. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery. 2002;132:127-134. [PMID: 12219002 DOI: 10.1067/msy.2002.124930] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.3] [Reference Citation Analysis]
17 Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, Repasky EA. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005;3:22. [PMID: 15943879 DOI: 10.1186/1479-5876-3-22] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 4.5] [Reference Citation Analysis]
18 Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Hanna N, Alexander HR, Hussain SP. FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Cancer Res 2013;73:5416-25. [PMID: 23801748 DOI: 10.1158/0008-5472.CAN-13-0362] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
19 Matsuda T, Almasan A, Tomita M, Uchihara JN, Masuda M, Ohshiro K, Takasu N, Yagita H, Ohta T, Mori N. Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines. J Virol 2005;79:1367-78. [PMID: 15650163 DOI: 10.1128/JVI.79.3.1367-1378.2005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ganten TM, Sykora J, Koschny R, Batke E, Aulmann S, Mansmann U, Stremmel W, Sinn HP, Walczak H. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) 2009;87:995-1007. [PMID: 19680616 DOI: 10.1007/s00109-009-0510-z] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
21 Wu CC, Chiang CY, Liu SJ, Chen HW. A Novel Recombinant Fcγ Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment. Biomedicines 2021;9:806. [PMID: 34356870 DOI: 10.3390/biomedicines9070806] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Xu F, Sun Y, Yang SZ, Zhou T, Jhala N, McDonald J, Chen Y. Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance. Int J Cancer 2019;145:474-83. [PMID: 30614530 DOI: 10.1002/ijc.32108] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
23 Dai J, Jin G, Dong J, Chen Y, Xu L, Hu Z, Shen H. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J Thorac Oncol 2010;5:1748-54. [PMID: 20881643 DOI: 10.1097/JTO.0b013e3181f18cb9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
24 Xiao M, Li W. Recent Advances on Small-Molecule Survivin Inhibitors. Curr Med Chem 2015;22:1136 - 1146. [PMID: 25613234 DOI: 10.2174/0929867322666150114102146] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
25 Wu M, Tong CWS, Yan W, To KKW, Cho WCS. The RNA Binding Protein HuR: A Promising Drug Target for Anticancer Therapy. Curr Cancer Drug Targets 2019;19:382-99. [PMID: 30381077 DOI: 10.2174/1568009618666181031145953] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
26 Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Mol Cancer Res 2016;14:599-611. [PMID: 27053682 DOI: 10.1158/1541-7786.MCR-15-0448] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
27 Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer. 2008;7:64. [PMID: 18652674 DOI: 10.1186/1476-4598-7-64] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
28 Mita MM, Mita AC, Tolcher AW. Apoptosis: mechanisms and implications for cancer therapeutics. Targ Oncol 2006;1:197-214. [DOI: 10.1007/s11523-006-0034-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
29 Hung C, Liu H, Huang M, Cheng C, Kuo L, Ho Y, Wu C, Chen C, Wei P, Chang Y. Knockdown Survivin Expression Reduces the Efficacy of Curcumin Treatment in Hepatocellular Carcinoma Cells. Ann Surg Oncol 2012;19:3547-55. [DOI: 10.1245/s10434-012-2393-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
30 Giri AK, Midha S, Banerjee P, Agrawal A, Mehdi SJ, Dhingra R, Kaur I, G RK, Lakhotia R, Ghosh S, Das K, Mohindra S, Rana S, Bhasin DK, Garg PK, Bharadwaj D; INDIPAN and INDICO Consortium. Common Variants in CLDN2 and MORC4 Genes Confer Disease Susceptibility in Patients with Chronic Pancreatitis. PLoS One 2016;11:e0147345. [PMID: 26820620 DOI: 10.1371/journal.pone.0147345] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
31 Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Ozdogan M, Suleymanlar I, Balci MK, Griffith TS, Sanlioglu S. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas 2009;38:154-60. [PMID: 18981952 DOI: 10.1097/MPA.0b013e31818db9e3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
32 Hwang KE, Kwon SJ, Kim YS, Park DS, Kim BR, Yoon KH, Jeong ET, Kim HR. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR. Exp Cell Res 2014;323:288-96. [PMID: 24631288 DOI: 10.1016/j.yexcr.2014.02.026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
33 Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N, Sasamata M. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leukemia Research 2011;35:787-92. [DOI: 10.1016/j.leukres.2010.11.016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
34 Farrow B, Thomas RP, Wang XF, Evers BM. Activation of conventional PKC isoforms increases expression of the pro-apoptotic protein Bad and TRAIL receptors. Int J Gastrointest Cancer 2002;32:63-72. [PMID: 12794242 DOI: 10.1385/IJGC:32:2-3:63] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
35 Hwang KE, Na KS, Park DS, Choi KH, Kim BR, Shim H, Jeong ET, Kim HR. Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs 2011;29:945-52. [PMID: 20464445 DOI: 10.1007/s10637-010-9450-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
36 Tekmen I, Ozyurt D, Pekçetin C, Buldan Z. The effect of TRAIL molecule on cell viability in in vitro beta cell culture. Acta Diabetol 2007;44:60-4. [PMID: 17530468 DOI: 10.1007/s00592-007-0243-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Chen LH, Liu XS, Wang WY, Han WN, Pan BR, Jin BQ. Localization of TRAIL/TRAILR in fetal pancreas. World J Gastroenterol 2003; 9(2): 334-337 [PMID: 12532461 DOI: 10.3748/wjg.v9.i2.334] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
38 Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Omer A, Griffith TS, Sanlioglu S. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas 2008;36:385-93. [PMID: 18437085 DOI: 10.1097/MPA.0b013e318158a4e5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
39 Tafuku S, Matsuda T, Kawakami H, Tomita M, Yagita H, Mori N. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma. Eur J Haematol 2006;76:64-74. [DOI: 10.1111/j.0902-4441.0000.t01-1-ejh2345.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]